Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB-ABDA Cause Oedema peripheral? 11 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Oedema peripheral have been filed in association with INFLIXIMAB-ABDA. This represents 0.6% of all adverse event reports for INFLIXIMAB-ABDA.

11
Reports of Oedema peripheral with INFLIXIMAB-ABDA
0.6%
of all INFLIXIMAB-ABDA reports
0
Deaths
5
Hospitalizations

How Dangerous Is Oedema peripheral From INFLIXIMAB-ABDA?

Of the 11 reports, 5 (45.5%) required hospitalization.

Is Oedema peripheral Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB-ABDA. However, 11 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB-ABDA Cause?

Off label use (493) Product use issue (272) Dyspnoea (145) Nausea (142) Crohn's disease (133) Arthralgia (131) Diarrhoea (118) Drug ineffective (111) Headache (111) Malaise (111)

What Other Drugs Cause Oedema peripheral?

AMBRISENTAN (2,959) TREPROSTINIL (2,816) ADALIMUMAB (2,356) LENALIDOMIDE (2,298) AMLODIPINE (2,076) PREDNISONE (2,029) METHOTREXATE (1,939) MACITENTAN (1,932) RITUXIMAB (1,698) TOCILIZUMAB (1,574)

Which INFLIXIMAB-ABDA Alternatives Have Lower Oedema peripheral Risk?

INFLIXIMAB-ABDA vs INFLIXIMAB-AXXQ INFLIXIMAB-ABDA vs INFLIXIMAB-DYYB INFLIXIMAB-ABDA vs INFLIXIMAB-QBTX INFLIXIMAB-ABDA vs INFLIXIMAB, RECOMBINANT INFLIXIMAB-ABDA vs INFLUENZA A VIRUS A/CALIFORNIA/7/2009 LIVE ANTIGEN\INFLUENZA A VIRUS A/TEXAS/50/2012 LIVE ANTIGEN\INFLUENZA B VIRUS B/BRISBANE/60/2008 LIVE ANTIGEN\INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 LIVE ANTIGEN

Related Pages

INFLIXIMAB-ABDA Full Profile All Oedema peripheral Reports All Drugs Causing Oedema peripheral INFLIXIMAB-ABDA Demographics